NASDAQ:ZEAL

Zealand Pharma A/S Stock Forecast, Price & News

$37.61

+0.01 (+0.03 %)

(As of 01/15/2021 08:00 PM ET)

Add

Compare

Today's Range

$37.61

Now: $37.61▼

$37.61

50-Day Range

$34.47

MA: $36.83▼

$38.75

52-Week Range

$22.00

Now: $37.61▼

$44.60

Volume1,800 shs

Average Volume5,660 shs

Market Capitalization$1.50 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.19

Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

MarketRank^™

Overall MarketRank^™

1.00 out of 5 stars

2.5 Analyst's Opinion

Consensus Rating
Zealand Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $43.00, Zealand Pharma A/S has a forecasted upside of 14.3% from its current price of $37.61.
Amount of Analyst Coverage
Zealand Pharma A/S has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Zealand Pharma A/S has received 286 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Zealand Pharma A/S has received 290 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Zealand Pharma A/S has received 50.35% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Zealand Pharma A/S and other stocks. Vote “Outperform” if you believe ZEAL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Zealand Pharma A/S does not currently pay a dividend.
Dividend Growth
Zealand Pharma A/S does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zealand Pharma A/S insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 4.32% of the stock of Zealand Pharma A/S is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Zealand Pharma A/S are expected to decrease in the coming year, from ($2.61) to ($3.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zealand Pharma A/S is -16.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zealand Pharma A/S is -16.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zealand Pharma A/S has a P/B Ratio of 6.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ZEAL

Previous Symbol

CUSIPN/A

CIK1674988

Webwww.zealandpharma.com

Phone45-8877-3600

Employees329

Debt

Debt-to-Equity RatioN/A

Current Ratio6.76

Quick Ratio6.51

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$6.20 million

Price / Sales241.40

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.85 per share

Price / Book6.43

Profitability

EPS (Most Recent Fiscal Year)($2.54)

Net Income$-85,670,000.00

Net Margins-214.31%

Return on Equity-38.34%

Return on Assets-30.40%

Miscellaneous

Outstanding Shares39,795,000

Market Cap$1.50 billion

Next Earnings Date3/11/2021 (Estimated)

OptionableNot Optionable

$37.61

+0.01 (+0.03 %)

(As of 01/15/2021 08:00 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter.

Zealand Pharma A/S (NASDAQ:ZEAL) Frequently Asked Questions

How has Zealand Pharma A/S's stock price been impacted by Coronavirus?

Zealand Pharma A/S's stock was trading at $28.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZEAL stock has increased by 33.8% and is now trading at $37.61.
View which stocks have been most impacted by COVID-19.

Is Zealand Pharma A/S a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zealand Pharma A/S stock.
View analyst ratings for Zealand Pharma A/S or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Zealand Pharma A/S?

Wall Street analysts have given Zealand Pharma A/S a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zealand Pharma A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zealand Pharma A/S's next earnings date?

Zealand Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Zealand Pharma A/S.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) issued its quarterly earnings results on Tuesday, November, 17th. The company reported ($5.76) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($5.58) by $0.18. The business earned $8.88 million during the quarter, compared to the consensus estimate of $16.41 million. Zealand Pharma A/S had a negative net margin of 214.31% and a negative return on equity of 38.34%.
View Zealand Pharma A/S's earnings history.

What price target have analysts set for ZEAL?

2 Wall Street analysts have issued 1 year price targets for Zealand Pharma A/S's shares. Their forecasts range from $42.00 to $44.00. On average, they expect Zealand Pharma A/S's stock price to reach $43.00 in the next twelve months. This suggests a possible upside of 14.3% from the stock's current price.
View analysts' price targets for Zealand Pharma A/S or view Wall Street analyst' top-rated stocks.

Who are some of Zealand Pharma A/S's key competitors?

Some companies that are related to Zealand Pharma A/S include Evotec (EVTCY), Emergent BioSolutions (EBS), Blueprint Medicines (BPMC), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Eidos Therapeutics (EIDX), Arena Pharmaceuticals (ARNA), Maravai LifeSciences (MRVI), Hutchison China MediTech (HCM), PTC Therapeutics (PTCT), Atea Pharmaceuticals (AVIR), Arvinas (ARVN), ChemoCentryx (CCXI), GW Pharmaceuticals (GWPH) and Reata Pharmaceuticals (RETA).
View all of ZEAL's competitors.

What other stocks do shareholders of Zealand Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zealand Pharma A/S investors own include AbbVie (ABBV), Galapagos (GLPG), Verizon Communications (VZ), Dynavax Technologies (DVAX), EyePoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Protalix BioTherapeutics (PLX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

Who are Zealand Pharma A/S's key executives?

Zealand Pharma A/S's management team includes the following people:

Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBA, CEO & Pres (Age 51)
Mr. Matthew Donald Dallas, Sr. VP & CFO (Age 45)
Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Representative Director (Age 67)
Mr. Adam Sinding Steensberg M.D., Exec. VP of R&D and Chief Medical Officer (Age 46)
Mr. Ivan Mourits MÃ¸ller, Sr. VP of Technical Devel. & Operations (Age 48)
Rie Schultz Hansen, Interim Chief Scientific Officer & VP of Research
Lani Pollworth Morvan, Investor Relations & Communications Officer
Mr. Mads Kronborg, Head of Investor Relations & Communication
SÃ¸ren Vitfell Keller, Head of Legal Affairs
Mr. Marino Garcia M.B.A., Sr. VP of Corp. & Bus. Devel. (Age 54)

When did Zealand Pharma A/S IPO?

(ZEAL) raised $75 million in an initial public offering on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Zealand Pharma A/S's stock symbol?

Zealand Pharma A/S trades on the NASDAQ under the ticker symbol "ZEAL."

How do I buy shares of Zealand Pharma A/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zealand Pharma A/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $37.61.

How big of a company is Zealand Pharma A/S?

Zealand Pharma A/S has a market capitalization of $1.50 billion and generates $6.20 million in revenue each year. The company earns $-85,670,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Zealand Pharma A/S employs 329 workers across the globe.

What is Zealand Pharma A/S's official website?

The official website for Zealand Pharma A/S is www.zealandpharma.com.

How can I contact Zealand Pharma A/S?

Zealand Pharma A/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The company can be reached via phone at 45-8877-3600 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here